Asenapine effects on individual Young Mania Rating Scale items in bipolar disorder patients with acute manic or mixed episodes: a pooled analysis

Pilar Cazorla
Jun Zhao
Mary Mackle
Armin Szegedi
Merck, Rahway, NJ, USA

Background: An exploratory post hoc analysis was conducted to evaluate the potential differential effects over time of asenapine and olanzapine compared with placebo on the eleven individual items comprising the Young Mania Rating Scale (YMRS) in patients with manic or mixed episodes in bipolar I disorder.

Methods: Data were pooled from two 3-week randomized, controlled trials in which the eleven individual items comprising the YMRS were measured over 21 days. An analysis of covariance model adjusted by baseline value was used to test for differences in changes from baseline in YMRS scores between groups.

Results: Each of the eleven individual YMRS item scores was significantly reduced compared with placebo at day 21. After 2 days of treatment, asenapine and olanzapine were superior to placebo for six of the YMRS items: disruptive/aggressive behavior, content, irritability, elevated mood, sleep, and speech.

Conclusion: Reduction in manic symptoms over 21 days was associated with a broad-based improvement across all symptom domains with no subset of symptoms predominating.

Keywords: asenapine, Young Mania Rating Scale, bipolar disorder, YMRS, antipsychotic, olanzapine

Introduction
The Young Mania Rating Scale (YMRS) is a diagnostic questionnaire commonly used to evaluate manic symptoms in patients with bipolar I disorder and to assess treatment efficacy in clinical trials. This rating scale comprises eleven items (elevated mood, increased motor activity – energy, sexual interest, sleep, irritability, speech – rate and amount, language–thought disorder, content, disruptive–aggressive behavior, appearance, and insight). The total YMRS score is calculated as the summation of each of the eleven individual item scores.¹

Asenapine is a tetracyclic antipsychotic with a unique pharmacologic profile indicated in several countries, including the United States and the European Union, for use in adult patients with manic episodes in bipolar I disorder. Acute efficacy was demonstrated in two 3-week trials in which asenapine monotherapy was significantly more effective than placebo at improving mania symptoms as assessed using the total YMRS score.² ³ The objective of this exploratory, post hoc analysis of the data pooled from the two positive trials was to identify the potential differential effects of asenapine or olanzapine on each of the eleven individual YMRS items, as indicators of the severity of specific bipolar mania symptom dimensions.
Materials and methods
Data were pooled from two 3-week randomized, placebo- and olanzapine-controlled, double-blind, double-dummy, multicenter, parallel-group trials (A7501004 and A7501005). Patients aged ≥18 years with a diagnosis of bipolar I disorder; current manic or mixed episodes according to the Mini International Neuropsychiatric Interview and Diagnostic and Statistical Manual of Mental Disorders, Fourth edition, text revision criteria; and a YMRS total score ≥20 at screening and baseline were eligible. Following a 7-day, single-blind placebo run-in phase, active treatment was initiated (day 1, n = 977) with asenapine 20 mg (10 mg twice daily [BID], morning and evening; n = 379), olanzapine 15 mg [once daily [QD]; n = 396], or placebo (n = 202). Thereafter, treatment continued with flexible dosing (asenapine at 10–20 mg daily [5–10 mg BID] and olanzapine at 5–20 mg QD). Patients remained in the research facility for ≥7 days of treatment and were discharged if clinically stable. A complete description of the design and eligibility criteria of both studies has been reported elsewhere.

Seven of the eleven individual YMRS items were scored on a 0 to 4 scale: appearance, insight, language–thought disorder, increased motor activity – energy, elevated mood, sleep, and sexual interest. The remaining four items were scored on a 0 to 8 scale: disruptive–aggressive behavior, content, irritability, and speech – rate and amount. The YMRS total score, with a range of 0 to 60, was a summation of each of the eleven individual scores, with the higher total YMRS score reflecting greater symptom severity. YMRS response rate was determined as the percentage of patients achieving ≥50% reduction from baseline in total YMRS score.

An exploratory post hoc analysis of the change from baseline in the eleven individual YMRS items was performed. An analysis of covariance model adjusted by baseline value was used to test for differences in changes from baseline in YMRS scores between groups. Last observations were carried forward (LOCF) for missing data. The results have not been corrected for multiplicity.

Results
Patient characteristics
Pooled patient demographics and baseline characteristics are displayed in Table 1. Of the 977 treated patients, 680 (70%) completed the studies. The modified intent-to-treat population (treated patients with at least one post baseline YMRS assessment, n = 960) consisted of patients receiving asenapine 10 to 20 mg daily (n = 372), olanzapine 5 to 20 mg daily (n = 391), or placebo (n = 197).

| Table 1 Pooled demographic and baseline characteristics (intent-to-treat) |
|----------------------------------------------------------|
| Sex, N | Placebo | Asenapine 10–20 mg daily | Olanzapine 5–20 mg daily |
|----------------------------------------------------------|
| Female, n (%) | 197 | 372 | 391 |
| Male, n (%) | 197 | 372 | 391 |
| Race, N | 197 | 372 | 391 |
| Asian, n (%) | 41 (20.8) | 75 (20.2) | 78 (19.9) |
| Black, n (%) | 34 (17.3) | 67 (18.0) | 71 (18.2) |
| White, n (%) | 110 (55.8) | 221 (59.4) | 221 (56.5) |
| Other, n (%) | 12 (6.1) | 9 (2.4) | 21 (5.4) |

Age group | 18–64 years, N (%) | 18–64 years, N (%) | ≥65 years, N (%) |
|--------------------------------------------------|
| 197 | 372 | 391 |
| ≥65 years, N (%) | 4 (2) | 7 (1.9) | 5 (1.3) |
| Age, N | 197 | 372 | 391 |
| Years, mean (SD) | 38.7 (12.2) | 38.8 (12.1) | 39.2 (11.1) |
| Current episode, N | 197 | 372 | 391 |
| Manic, n (%) | 131 (66.5) | 265 (71.2) | 269 (68.8) |
| Mixed, n (%) | 66 (33.5) | 107 (28.8) | 122 (31.2) |
| Weight, N | 197 | 372 | 391 |
| Kg, mean (SD) | 78 (19.5) | 76.9 (19.3) | 78.9 (19.9) |
| BMI, N | 196 | 371 | 389 |
| Kg/m², mean (SD) | 27.3 (6.1) | 26.5 (5.5) | 27.2 (5.9) |

Abbreviations: BMI, body mass index; SD, standard deviation.

YMRS item results
Reductions from baseline to day 21 were significantly greater for asenapine and olanzapine compared with placebo for each of the eleven individual YMRS items (Table 2). Statistically significant reductions in YMRS total score were observed for both treatments compared with placebo, as reported previously.

In six of the YMRS items, statistically significant improvements from baseline were observed as early as Day 2 (mean change ± SD, LOCF) for asenapine (10–20 mg daily) and olanzapine (5–20 mg daily) compared with placebo: disruptive–aggressive behavior (−0.3 ± 1.15; −0.4 ± 1.14; −0.1 ± 1.16), content (−0.4 ± 1.22; −0.5 ± 1.48; −0.2 ± 0.90), irritability (−0.5 ± 1.41; −0.5 ± 1.33; −0.3 ± 1.15), elevated mood (−0.3 ± 0.75; −0.3 ± 0.73; −0.1 ± 0.63), sleep (−0.4 ± 0.88; −0.5 ± 0.92; −0.2 ± 0.74), and speech (−0.6 ± 1.23; −0.6 ± 1.27; −0.1 ± 0.96) (all comparisons P < 0.05 for asenapine or olanzapine versus placebo).

No statistical difference was observed in the improvements seen with asenapine and olanzapine in the YMRS items of appearance, content, elevated mood, increased motor activity and insight. For the remaining items (language–thought disorder, sleep, sexual interest, disruptive–aggressive behavior, irritability, and speech) while both treatments were associated with significant improvement compared to placebo, olanzapine treatment was accompanied by a
|                     | Placebo | Asenapine 10–20 mg daily | Olanzapine 5–20 mg daily |
|---------------------|---------|--------------------------|--------------------------|
| **Day 21, n**       | 197     | 372                      | 391                      |
| **Baseline mean (SD)** | 28.7 (6.2) | 28.8 (6.2) | 29.2 (6.3) |
| **LS mean change (SE)** | −6.7 (0.75) | −11.2 (0.54) | −13.6 (0.53) |
| **P-value (versus placebo)** | <0.0001 | 0.0013 | <0.0001 |
| **P-value (versus olanzapine)** |          |                          |                          |
| **Appearance (0–4)** | 1.2 (0.80) | 1.2 (0.86) | 1.3 (0.94) |
| **LS mean change (SE)** | −0.3 (0.06) | −0.5 (0.04) | −0.6 (0.04) |
| **P-value (versus placebo)** | 0.0042 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.0518 |                          |                          |
| **Insight (0–4)**   | 1.0 (1.26) | 1.1 (1.38) | 1.1 (1.36) |
| **LS mean change (SE)** | −0.2 (0.06) | −0.4 (0.04) | −0.5 (0.04) |
| **P-value (versus placebo)** | 0.0035 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.115 |                          |                          |
| **Language–thought disorder (0–4)** | 2.1 (0.63) | 2.1 (0.66) | 2.1 (0.70) |
| **LS mean change (SE)** | −0.5 (0.06) | −0.8 (0.05) | −1.0 (0.05) |
| **P-value (versus placebo)** | 0.0008 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.0078 |                          |                          |
| **Increased motor activity – energy (0–4)** | 2.8 (0.69) | 2.8 (0.71) | 2.8 (0.66) |
| **LS mean change (SE)** | −0.8 (0.09) | −1.1 (0.06) | −1.2 (0.06) |
| **P-value (versus placebo)** | 0.0023 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.12 |                          |                          |
| **Elevated mood (0–4)** | 2.6 (0.88) | 2.7 (0.86) | 2.6 (0.85) |
| **LS mean change (SE)** | −0.6 (0.08) | −1.0 (0.06) | −1.1 (0.05) |
| **P-value (versus placebo)** | 0.0002 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.2696 |                          |                          |
| **Sleep (0–4)**     | 2.3 (0.84) | 2.2 (0.92) | 2.2 (0.92) |
| **LS mean change (SE)** | −0.6 (0.08) | −1.0 (0.06) | −1.2 (0.06) |
| **P-value (versus placebo)** | <0.0001 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.0067 |                          |                          |
| **Sexual interest (0–4)** | 1.5 (1.16) | 1.5 (1.11) | 1.6 (1.16) |
| **LS mean change (SE)** | −0.4 (0.07) | −0.6 (0.05) | −0.8 (0.05) |
| **P-value (versus placebo)** | 0.0101 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.0178 |                          |                          |
| **Disruptive–aggressive behavior (0–8)** | 2.9 (1.65) | 2.8 (1.60) | 2.9 (1.59) |
| **LS mean change (SE)** | −0.3 (0.13) | −1.0 (0.09) | −1.3 (0.09) |
| **P-value (versus placebo)** | <0.0001 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.0134 |                          |                          |
| **Content (0–8)**   | 4.2 (2.17) | 4.3 (2.10) | 4.3 (2.14) |
| **LS mean change (SE)** | −0.9 (0.15) | −1.7 (0.11) | −1.9 (0.11) |
| **P-value (versus placebo)** | <0.0001 |                          | <0.0001 |
| **P-value (versus olanzapine)** | 0.1517 |                          |                          |
| **Irritability (0–8)** | 3.9 (1.39) | 3.7 (1.51) | 4.0 (1.40) |
| **LS mean change (SE)** | −0.8 (0.13) | −1.3 (0.10) | −1.7 (0.09) |

(Continued)
Clinicians can therefore expect clinically relevant benefits early in the course of treatment, at least in a subset of patients. In this context, it is worthwhile to mention that early improvement has been reported to be associated with an increased odds ratio of response or remission at the end of treatment.6

Acknowledgments
Medical writing assistance was provided by Karen Pemberton, PhD, of PPSI (a PAREXEL company). The study was funded by Merck. PC is currently employed by Novartis, East Hanover, NJ, USA.

Disclosure
All authors were employees and shareholders of Merck at the time the study was performed. The authors report no other conflicts of interest in this work.

References
1. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry. 1978;133:429–435.
2. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009;11(7):673–686.
3. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010;122(1–2):27–38.
4. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 20):22–33.
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed, text rev). Washington, DC: American Psychiatric Association; 2000.
6. Zhao J, Ha X, Szegezi A. Early improvement predicts later outcome in manic or mixed episodes associated with bipolar i disorder: post hoc analyses of asenapine studies. Paper presented at: 63rd Annual Institute on Psychiatric Services Meeting. October 27–30, 2011; San Francisco, CA, USA.
Asenapine effects on Young Mania Rating Scale